Search Results
Your search for ,maY matches 16623 pages
Showing 10201 - 10250Novel Imaging Method for Predicting Immunotherapy Response
Although cancer immunotherapy can produce dramatic responses, only a minority of patients benefit from such therapy. Being able to differentiate treated responders from nonresponders early in the course of therapy would help to triage nonresponding patients away from ineffective therapies, reducing ...
Second Cancers May Be Deadlier in Pediatric, Adolescent, and Young Adult Patients
Second cancers in children as well as adolescents and young adults (AYAs) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients aged 15 to 39 years overall, according to a new study by University of California (UC), Davis...
FDA Grants Lorlatinib Breakthrough Therapy Designation for ALK-Positive Metastatic Non–Small Cell Lung Cancer
On April 27, the investigational next-generation ALK/ROS1 tyrosine kinase inhibitor lorlatinib was granted Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell...
ELCC 2017: Patients With Lung Cancer Treated With PD-1/PD-L1 Checkpoint Inhibitors May Experience Adverse Events After Influenza Vaccination
Patients with lung cancer treated with programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) checkpoint inhibitors may be at increased risk of adverse events after receiving the seasonal influenza vaccination, according to the first study measuring this effect. The results, to ...
Joint Position Statement on Management of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Hormone-Sensitive Breast Cancer
A new position statement, jointly published by seven international and European organizations, identifies fracture-related risk factors in patients treated with aromatase inhibitors and outlines key management strategies to help prevent bone loss and related fractures. It was published by Hadji et...
Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment
In newly updated clinical guidelines from the Society for Integrative Oncology (SIO), researchers at Columbia University's Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center, along with an interdisciplinary team of colleagues at The University of Texas MD Anderson...
FDA Takes Action Against 14 Companies for Selling Illegal Cancer Treatments
On April 25, the U.S. Food and Drug Administration (FDA) posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat, or cure cancer. The products are marketed and sold without FDA approval, most commonly on ...
ILC 2017: Selective Internal Radiation Therapy vs Sorafenib in Hepatocellular Carcinoma
Results of the SARAH trial presented at the 2017 International Liver Congress (ILC) demonstrated that selective internal radiation therapy (SIRT) resulted in a median overall survival of 8.0 months compared to 9.9 months with sorafenib (Nexavar; P = .179) in patients with locally advanced ...
Noninvasive Imaging Test May Accurately Rule Out Kidney Cancers
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT (single-photon emission computed tomography plus computed tomography) to conventional CT or magnetic resonance imaging...
Neoadjuvant Chemotherapy for Breast Cancer and Risk for Local Metastases
A pathologic complete response to presurgical therapy occurs in between 40% and 50% of patients with HER2-positive and triple-negative breast cancer, raising the question of the need for surgery for all patients after neoadjuvant chemotherapy indicates a pathologic complete response in...
Efficacy Analysis of ABC Breast Cancer Trials of Adjuvant Taxane With/Without Anthracycline in HER2-Negative Disease
As reported by Blum et al in the Journal of Clinical Oncology, the efficacy analysis of the combined adjuvant Anthracyclines in Early Breast Cancer (ABC) Trials showed better invasive disease-free survival with taxane plus doxorubicin/cyclophosphamide (TaxAC) regimens vs six cycles of...
Higher Rates of Bone Metastases and Increased Risk of Death in Follicular and Medullary Thyroid Cancer
In the largest-known study on bone metastases in thyroid cancer, researchers at the University of Michigan Comprehensive Cancer Center found that patients with follicular and medullary thyroid cancer had the highest rate of cancer-related bone lesions and fractures and an increased risk of death....
Predictors of Adherence to Oral Chemotherapy
In a single-center study reported in the Journal of Oncology Practice, Jacobs et al found that improved satisfaction with clinician communication and treatment was the strongest predictor of treatment adherence in patients receiving oral anticancer medication. Study Details The prospective study...
21-Gene Assay Score and Chemotherapy Decision-Making in Node-Positive Early Breast Cancer
The 21-gene recurrence score assay, Oncotype DX, determines a score that estimates the likelihood of distant recurrence of disease in women with early-stage estrogen receptor–positive breast cancer; this score is used to assess the benefit of adjuvant chemotherapy. Testing with this assay is...
Study Associates Comorbidities With Survival Outcomes in Women With Ovarian Cancer
Research from epidemiologists at Roswell Park Cancer Institute, published by Minlikeeva et al in Cancer Causes & Control, suggests that hypertension and diabetes and the use of medications to treat these comorbidities may have an effect on survival outcomes in women with ovarian cancer. Study...
Update to ASCO Clinical Practice Guideline on Potentially Curable Pancreatic Cancer
An ASCO clinical practice guideline update, reported by Khorana et al in the Journal of Clinical Oncology, includes the recommendation of gemcitabine-capecitabine doublet therapy as an adjuvant therapy option in potentially curable pancreatic cancer. The updated recommendation (4.1) modifies the...
Utilizing Physiatrists to Evaluate and Manage Cancer-Related Cognitive Impairment
Chemotherapy-associated cognitive dysfunction, often referred to as “chemobrain” or “chemofog,” is a common occurrence during active cancer treatment and may continue after treatment is completed. However, since treatment other than chemotherapy, including radiation therapy, surgery, and hormonal...
Olaparib Maintenance in Ovarian Cancer: Outcomes Reconsidered
An article that appeared in the April 10 issue of The ASCO Post (“Olaparib Maintenance Prolongs Progression-Free Survival in Ovarian Cancer”) suggests unwarranted conclusions from the phase III SOLO2 trial of olaparib (Lynparza) in patients with platinum-sensitive relapsed ovarian cancer and...
Addition of Buparlisib to Paclitaxel in Squamous Cell Carcinoma of the Head and Neck
In the phase II BERIL-1 trial reported in The Lancet Oncology, Soulières et al found that adding the pan-PI3K (phosphatidylinositol 3-kinase) inhibitor buparlisib to paclitaxel improved outcomes in patients with platinum-pretreated recurrent metastatic squamous cell carcinoma of the head and neck....
Expect Questions About Continued Risk of Melanoma
Survivors of melanoma are more likely to limit their exposure to ultraviolet radiation than those who have not had the disease, but more than 10% continue to intentionally tan, according to a study published in Cancer Epidemiology, Biomarkers and Prevention.1 The study surveyed 724 people diagnosed ...
Some Melanoma Survivors Continue to Seek Sun Exposure, Risking Second, Potentially More Serious Melanoma
Long-term survivors of melanoma are more likely than those who have not been diagnosed with the disease to use sunscreen, protective clothing, and other means to limit exposure to the sun, according to a survey of melanoma survivors and controls about ultraviolet radiation exposure and protective...
Better Vision Function May Be Related to Better Quality of Life in Patients With Head and Neck Cancer
Better vision function seems to be related to better quality of life after treatment for head and neck cancer, particularly among patients who have had surgery, according to Hsiao-Lan Wang, PhD, RN, Assistant Professor in the College of Nursing at the University of South Florida. Head and neck...
Living Beyond Breast Cancer Translates Metastatic Breast Cancer Guide Into Five Languages
Living Beyond Breast Cancer (LBBC) has translated its Metastatic Breast Cancer Series: Guide for the Newly Diagnosed into the five most-often-spoken languages in the United States after English: Spanish, Chinese, Vietnamese, Tagalog, and French. Jointly created by LBBC and the Metastatic Breast...
Carlo M. Croce, MD, FAACR, Recognized With 2017 AACR Margaret Foti Award
The American Association for Cancer Research (AACR) recognized Carlo M. Croce, MD, FAACR, with the 11th Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the AACR Annual Meeting 2017 in Washington, DC. The Margaret Foti Award for Leadership and...
Using Geriatric Assessment Strategies to Inform Patient-Centered End-of-Life Care
End-of-life care in any patient with cancer is challenging for the patient, family, and physician. Issues faced at the end of life include pain, depression, loss of dignity, and hopelessness. In the geriatric patient, additional complexities are present in the form of comorbid conditions,...
Accelerating Pediatric Drug Development: Master Protocols May Be a Way to Go
Development of pediatric cancer drugs has long lagged behind adult drug development for two major reasons: The process is more difficult, and childhood cancer is rarer by far than adult cancer. These and other phenomena in pediatric oncology were the subject of a workshop held by the Friends of...
Monoclonal Antibody Therapy With Daratumumab in Multiple Myeloma: Expanding Therapeutic Horizons
The advent of successful monoclonal antibody therapy in the treatment of relapsed/refractory myeloma has dramatically improved the prognosis of patients for whom currently approved novel therapies have failed. In 2015, the approval of the combination of elotuzumab (Empliciti) with lenalidomide...
Updated Data on Treatment With Ibrutinib and Venetoclax in Patients With CLL/SLL
Long-term follow-up of treatment with ibrutinib (Imbruvica) in patients with previously untreated and treated chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) has shown high response rates that are durable. At 5 years, 89% of patients with treatment-naive and relapsed or...
Treating Human Immunodeficiency Virus–Related Lymphoma
Alexandra Levine, MD, MACP, is Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, Duarte, California, and has been on the front lines of the AIDS epidemic from the beginning—before the disease even had a name. Dr. Levine spoke with The ASCO Post about ...
Treatment of Diffuse Large B-Cell Lymphoma Continues to Evolve
Although the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) has improved with R-CHOP—the addition of rituximab (Rituxan) to the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen—one-third of patients still relapse after therapy, and patients with the ...
Expert Point of View: Eric Jonasch, MD
Eric Jonasch, MD, Professor in the Department of Genitourinary Cancer at MD Anderson Cancer Center in Houston, commented on this phase II study. “This is an important study, since we have, for the first time, randomized, prospective data comparing the combination of a checkpoint antibody with an...
Combination of Atezolizumab and Bevacizumab in PD-L1–Positive Patients With Metastatic Kidney Cancer
The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) appears to be promising in the first-line treatment of patients with metastatic renal cell carcinoma, according to results of a phase II trial presented at the 2017 Genitourinary Cancers Symposium.1 Despite the failure of the...
Stage I Lung Cancer: Treatment Advances Have Changed the Game
Read more in the Journal of Oncology Practice (JOP). Visit ASCOPubs.org/journal/jop Patients with stage I lung cancer are achieving excellent local tumor control, thanks to an evolution in radiotherapy and surgical approaches. Jeffrey A. Bogart, MD, Professor and Chair of the Department of...
Institute for Clinical Immuno-Oncology White Paper Highlights Challenges, Progress, and Priorities in Immunotherapy
Momentum around immunotherapies for cancer continues to build, but the high cost of these therapies places them at the center of debate about how best to define and measure value in cancer care. As these therapies are increasingly integrated into practice, all stakeholders—providers, patients,...
CAR T-Cell Therapy Shows Benefit in Patients With Treatment-Resistant Chronic Lymphocytic Leukemia
Researchers from Fred Hutchinson Cancer Research Center in Seattle reported early results from a small study of their chimeric antigen receptor (CAR) T-cell product (JCAR014) in chronic lymphocytic leukemia (CLL) at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition....
Expert Point of View: Prof. Noel Clarke, MBBS, FRCS, ChM
Formal discussant of the 111 trial, Prof. Noel Clarke, MBBS, FRCS, ChM, The Christie Hospital, Manchester, UK, had some concerns, but overall felt that the study could be practice-changing. “In this paper, single-cycle treatment is safe and effective, and two cycles of adjuvant BEP (bleomycin,...
Two Studies Show Potential of Venetoclax as Single Agent and in Combination for Myeloma
Early-phase studies suggest that venetoclax (Venclexta) holds promise as a treatment for myeloma. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, investigators reported strong activity in heavily pretreated patients, especially those with the t(11;14)...
FNIH Awards Lurie Prize in Biomedical Sciences to David M. Sabatini, MD, PhD
The Foundation for the National Institutes of Health (FNIH) has selected David M. Sabatini, MD, PhD, to receive its 5th annual Lurie Prize in Biomedical Sciences for discovery of the mTOR (mechanistic target of rapamycin) cellular pathway as a key regulator of growth and metabolism in response to...
Different Subtypes of Acute Myeloid Leukemia Create Both Clinical and Research Challenges
Acute myeloid leukemia (AML) is the most common leukemia in adults. Each year, about 20,000 Americans will be diagnosed with AML, and roughly 10,000 people in this country will die of the disease. AML progresses quickly, and unless treatment begins soon and is effective , the prognosis is grim....
Cranberry
Scientific Name: Vaccinium macrocarpon Common Names: Mossberry, sassamanash, bounceberry Case Study M.C. is a 55-year-old woman with a history of stage I endometrial cancer, diagnosed and curatively treated 5 years ago. Since then, she has been having urinary tract infections from time to time....
Progress in Defining Molecular Signature for Aggressive Androgen-Indifferent Prostate Cancer
Prostate cancer has lagged behind breast cancer in the identification of predictive and prognostic biomarkers, but the field is catching up. Researchers have identified a molecular signature that can distinguish aggressive prostate cancer that is androgen-indifferent and will have a better response ...
Research Reveals New Treatment Possibilities for Prostate Cancer
Not all cancer research will result in a positive outcome for patients, but all research does provide information that continues to advance the treatment of cancer care. Recent clinical trials, including one funded in part by the Conquer Cancer Foundation (CCF) of ASCO, show that most prostate...
Breath Test Might Help Detect Stomach and Esophageal Cancers
A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the esophagus and stomach, in a large patient trial presented by Markar et al at the 2017 European Cancer Congress (Abstract 6LBA).1 Together, stomach and esophageal cancers...
Onset of Diabetes or Its Rapid Deterioration Can Be an Early Warning Sign of Pancreatic Cancer
The onset of diabetes, or a rapid deterioration in existing diabetes that requires more aggressive treatment, could be a sign of early, hidden pancreatic cancer, according to research presented by Autier et al at the 2017 European Cancer Congress (Abstract 540).1 Study Design and Key Findings...
Rucaparib Leads to Frequent Durable Remissions in BRCA-Mutated Relapsed Ovarian Cancer
Rucaparib (Rubraca) led to frequent durable remissions among patients with relapsed high-grade ovarian cancer with BRCA mutations, regardless of whether the mutations were germline or somatic, according to the results of the ARIEL2 trial presented at the 2017 Society of Gynecologic Oncology Annual...
Decision Aid Improves Breast Cancer Patients’ Knowledge of Surgical Options
A Web-based decision aid that allows women with early breast cancer to easily compare surgical treatment options helps them make more informed decisions, suggests a randomized trial reported at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 “Having knowledge of surgical...
Expert Point of View: Kelly M. McMasters, MD, PhD
“Several gene-expression profiles have been evaluated to predict prognosis in colorectal cancer, but none have become widely accepted or U.S. Food and Drug Administration–approved. This has important implications for deciding which patients may benefit from adjuvant chemotherapy,” commented...
Machine Learning Model Predicts Colorectal Cancer Recurrence
A machine learning model that uses a set or ensemble of algorithms has good accuracy for predicting colorectal cancer recurrence, investigators reported during a plenary session at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 Persistent key questions in managing early...
FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Some Advanced Bladder Cancers
On April 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab (Tecentriq) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Atezolizumab was previously approved for people...
ASCO Releases Position Statement on Access to Investigational Drugs
ASCO strongly supports increasing access to investigational new treatment options for patients with cancer, while raising serious concerns about recently proposed federal “right-to-try” legislation as well as state-enacted right-to-try laws. In a position statement released April 4, 2017, ASCO said ...
